



## Freedom of Information Request: Our Reference CTMUHB\_141\_26

### You asked:

I am submitting a request under the Freedom of Information Act 2000.

Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:

### **1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years.**

Our pharmacy department are only able to give the numbers of Kenalog issued for the last three financial years; the total of which is 185 as quoted in the response to Question 5. We cannot confirm how many were administered to patients.

### **2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post-operative inflammation), if available.**

Clinical indications include:

Inflammatory eye conditions – Uveitis, Scleritis and Episcleritis

Postoperative inflammation – cataract surgery

Allergic reactions – severe allergic conjunctivitis

Ocular surface disorders – pterygium, corneal inflammation

Retinal conditions – diabetic macular oedema

Other – Vitreous haemorrhage, Choroidal neovascularisation.

### **3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology.**

Guidelines and recommendations for prescribing are in accordance with:

- NICE guidelines
- RCOphth guidelines
- BOPG recommendations

### **4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period.**

We have carried out a search of Datix (our internal reporting system) and can confirm that there have been no incidents recorded in the last three years or since we went live with Datix Cymru Incidents module back in April 2022 (re. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology).

### **5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held.**

**6. Whether Kenalog (triamcinolone) is listed on the Trust's formulary for Ophthalmology, and if so, any restrictions or criteria for its use.**

Kenalog (triamcinolone) is not listed on the CTMUHB formulary. All licensed products have been discontinued.

**7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to:**

- **whether the Ophthalmology department is continuing to use existing stock,**
- **any plans or decisions to discontinue its use, and**
- **any identified or recommended alternative treatments.**

Following appropriate searches, Cwm Taf Morgannwg University Health Board can confirm that it does not hold any recorded information, internal communications, policies, or decisions relating to the withdrawal of Kenalog from the UK market within the scope of your request.

Under section 1(1)(a) of the Freedom of Information Act 2000, we can confirm that this information is not held by the Health Board.